AIkido Pharma Inc. Provides Update on Timing of Record Date and Anticipated Distribution Date for Dividend Distribution

NEW YORK, March 27, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the record date and distribution date to our stockholders of shares of Hoth Therapeutics, Inc. (“Hoth”) will be deferred because of the requirement that the shares be registered prior to distribution.  AIkido will provide a record date and distribution date for the distribution of the shares promptly once the registration statement is declared effective and will issue an update to shareholders in two weeks on the status of this matter.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:     

Hayden IR

Brett Maas, Managing Partner

Phone: (646) 536-7331

Email: brett@haydenir.com

www.haydenir.com

AIkido:       

Phone: 212-745-1373

Email: investorrelations@AIkido.com

www.AIkido.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-provides-update-on-timing-of-record-date-and-anticipated-distribution-date-for-dividend-distribution-301031161.html

SOURCE AIkido Pharma Inc.

Staff

Recent Posts

Promino Announces Closing of Private Placement

Burlington, Ontario--(Newsfile Corp. - January 30, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC:…

4 hours ago

NuGen Medical Devices Inc. Announces CFO Transition

Toronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

6 hours ago

Midmark RTLS launches BLE Sensory Network for smarter, scalable RTLS

New Plug-In BLE Sensors provide a faster, more cost-effective path to facility-wide RTLS coverage with near-room…

6 hours ago

Vrtly, Inc. Unveils End-to-End In-Practice Marketing Platform, Bridging the “Blind Spot” for Brands in Cash-Pay Healthcare

DANVILLE, Calif., Jan. 30, 2026 /PRNewswire/ -- Vrtly, Inc., the premier point-of-care (POC) marketing platform…

6 hours ago

Frontage Laboratories Expands Early Phase Clinical Capabilities to Support Global Drug Development

EXTON, Pa., Jan. 30, 2026 /PRNewswire/ -- Frontage Laboratories, Inc. ("Frontage"), a global Contract Research,…

6 hours ago